Lifeward Logs 14% Revenue Decline, Secures Oomed Capital Deal and Scalable IP
Lifeward's Q4 report showed a 14% decline in annual revenue and high operating expenses despite decreased costs. The company closed a strategic capital deal with Oomed, acquired Scalable's IP for advanced rehabilitation technologies, secured Medicare Advantage reimbursement for Rewalk, and expanded European distribution.
1. Q4 Financial Performance
Lifeward reported a 14% year-over-year decrease in revenue for 2025, driven by lower Ultra G sales and transitional costs. Operating expenses remained elevated despite reductions, pressuring margins and prompting the company to withhold forward guidance.
2. Strategic Transactions
The company finalized a capital infusion from Oomed, bolstering its financial foundation for ongoing R&D. Lifeward also acquired Scalable’s intellectual property portfolio to accelerate development of next-generation rehabilitation devices.
3. Reimbursement and Distribution Progress
Rewalk secured coverage under major Medicare Advantage plans, expanding patient access and potential sales. International distribution gained traction in Europe, where new partnerships aim to drive regional adoption of Lifeward’s neurorehabilitation offerings.
4. Operational Challenges and Outlook
Lifeward’s shift to a hybrid U.S. sales model has yet to boost top-line growth, and distributor dynamics hurt Ultra G volumes. High expenses and strategic transformations create uncertainty, leading management to pause issuing guidance.